[HTML][HTML] Minimal change disease

M Vivarelli, L Massella, B Ruggiero… - Clinical Journal of the …, 2017 - journals.lww.com
Minimal change disease (MCD) is a major cause of idiopathic nephrotic syndrome (NS),
characterized by intense proteinuria leading to edema and intravascular volume depletion …

Primary glomerulonephritides

J Floege, K Amann - The Lancet, 2016 - thelancet.com
Most glomerulonephritides, even the more common types, are rare diseases. They are
nevertheless important since they frequently affect young people, often cannot be cured, and …

Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy

P Ruggenenti, H Debiec, B Ruggiero… - Journal of the …, 2015 - journals.lww.com
Rituximab induces nephrotic syndrome (NS) remission in two-thirds of patients with primary
membranous nephropathy (MN), even after other treatments have failed. To assess the …

Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind …

K Iijima, M Sako, K Nozu, R Mori, N Tuchida, K Kamei… - The Lancet, 2014 - thelancet.com
Background Rituximab could be an effective treatment for childhood-onset, complicated,
frequently relapsing nephrotic syndrome (FRNS) and steroid-dependent nephrotic …

Long-term efficacy and safety of repeated rituximab to maintain remission in idiopathic childhood nephrotic syndrome: an international study

EY Chan, LM Ellen, A Angeletti, Z Arslan… - Journal of the …, 2022 - journals.lww.com
Background Long-term outcomes after multiple courses of rituximab among children with
frequently relapsing, steroid-dependent nephrotic syndrome (FRSDNS) are unknown …

B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome

M Colucci, R Carsetti, S Cascioli… - Journal of the …, 2016 - journals.lww.com
The pathogenesis of nephrotic syndrome is unclear. However, the efficacy of rituximab, a B
cell–depleting antibody, in nephrotic syndrome suggests a pathogenic role of B cells. In this …

Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial

P Ravani, R Rossi, A Bonanni, RR Quinn… - Journal of the …, 2015 - journals.lww.com
Steroid-dependent nephrotic syndrome (SDNS) carries a high risk of toxicity from steroids or
steroid-sparing agents. This open-label, noninferiority, randomized controlled trial at four …

Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial

B Basu, A Sander, B Roy, S Preussler, S Barua… - JAMA …, 2018 - jamanetwork.com
Importance Calcineurin inhibitors are an established first-line corticosteroid-sparing therapy
for patients with corticosteroid-dependent nephrotic syndrome (CDNS), whereas B …

Immunology of idiopathic nephrotic syndrome

M Colucci, G Corpetti, F Emma, M Vivarelli - Pediatric Nephrology, 2018 - Springer
The pathogenesis of idiopathic nephrotic syndrome (INS) is as yet unknown, but several
lines of evidence indicate that the immune system may play a crucial pathogenic role in non …

Rituximab for nephrotic syndrome in children

K Iijima, M Sako, K Nozu - Clinical and experimental nephrology, 2017 - Springer
Idiopathic nephrotic syndrome is the most common chronic glomerular disease in children.
At least 20% of children with this syndrome show frequent relapses and/or steroid …